keap1-nrf2 ppi-in-1

KEAP1-NRF2PPI-IN-1 (compound 23) is an inhibitor targeting the KEAP1-NRF2 interaction. In DNA damage tests, its IC50 values are 136 nM in human TK6 cell lines and 62 nM in insect SF9 cell lines.

NXPZ-2 is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor (Ki: 95 nM, EC50: 120 and 170 nM). NXPZ-2 dose-dependently attenuates Aβ[1-42]-induced cognitive disturbances, enhances neuronal number and function, and improves pathological alterations in the brain of Alzheimer's disease (AD) mice. NXPZ-2 has potential for studies of Keap1-Nrf2 PPI inhibitors and AD-related disorders.

Keap1-Nrf2-IN-9 (compound 11) is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI) with an IC50 value of 0.575 µM, enhancing the expression of Nrf2 target genes such as heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and glutamate-cysteine ligase catalytic (Gclc) and modulatory (Gclm) subunits, while not being cytotoxic to ARPE19 cells [1].

Tricetin is a flavonoid isolated from pomegranate.Tricetin is a potent competitive inhibitor of Keap1-Nrf2 protein-protein interaction (PPI) and protects Parkinson's disease patients from 6-OHDA-induced neurotoxicity by activating the Nrf2 HO-1 signaling pathway and blocking mitochondria-dependent apoptotic pathways.Tricetin Inhibits migration and expression of the indicator protease progerin-1 (PS-1) in nasopharyngeal carcinoma through the Akt GSK-1β pathway.Tricetin inhibits endothelial inflammation induced by oxidized LDL mediated by Egr-1, and protects rat chondrocytes from IL-1β-induced inflammation and apoptosis.Tricetin is an inhibitor of endothelial inflammation induced by oxidized LDL mediated by Egr-1 and protects against IL-1β-induced inflammation and apoptosis.